Nov 3, 2025 08:01AM Prime Medicine names Matthew Hawryluk as chief business officer

Aug 13, 2025 07:09AM Prime Medicine (PRME) PT Lowered to $5 at Guggenheim

Aug 8, 2025 04:22PM Prime Medicine (PRME) PT Lowered to $10 at Chardan Capital Markets, 'Cash Runway Breathing Room'

Aug 7, 2025 08:37AM Prime Medicine, Inc. (PRME) Tops Q2 EPS by 2c

Jul 21, 2025 04:12AM Citizens JMP Reiterates Market Outperform Rating on Prime Medicine (PRME)

Jul 17, 2025 06:49AM H.C. Wainwright Reiterates Neutral Rating on Prime Medicine (PRME)

Jul 16, 2025 07:01AM Prime Medicine receives up to $24 million from Cystic Fibrosis Foundation

Jun 18, 2025 04:47AM Citizens JMP Reiterates Market Outperform Rating on Prime Medicine (PRME)

Jun 18, 2025 04:45AM Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP

May 27, 2025 03:49AM Citi Downgrades Prime Medicine (PRME) to Neutral, 'Financing Risk Muddles the Path to Value Inflection'

May 20, 2025 04:12AM Prime Medicine (PRME) PT Lowered to $6 at Citizens JMP

May 19, 2025 04:22PM JPMorgan Downgrades Prime Medicine (PRME) to Neutral

May 19, 2025 01:12PM Prime Medicine (PRME) PT Lowered to $12 at Chardan Capital Markets

May 19, 2025 10:37AM Prime Medicine (PRME) PT Lowered to $9 at Jefferies

May 19, 2025 10:28AM Citi on Prime Medicine (PRME) with shares down 20pct: 'Initial Human Data from a Prime Editing Therapy Show Promise, but Financing Risk Remains a Key Overhang'

May 19, 2025 08:32AM Prime Medicine (PRME) Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 8, 2025 05:02PM Prime Medicine, Inc. (PRME) Tops Q1 EPS by 4c

Mar 20, 2025 06:28AM Prime Medicine (PRME) PT Lowered to $16 at Chardan Capital Markets

Mar 19, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)

Mar 19, 2025 04:12AM Citizens JMP Reiterates Market Outperform Rating on Prime Medicine (PRME)

Mar 18, 2025 07:01AM Prime Medicine (PRME) Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency

Mar 4, 2025 04:34AM Citizens JMP Reiterates Market Outperform Rating on Prime Medicine (PRME)

Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'

Jan 3, 2025 01:22PM Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Dec 20, 2024 12:46PM BMO Capital Highlights Favorite Names for 2025 in Biotech

Dec 13, 2024 08:21AM Prime Medicine (PRME) Files for 11M Share Offering by Selling Stockholders

Dec 10, 2024 03:18AM JMP Securities Starts Prime Medicine (PRME) at Market Outperform

Nov 13, 2024 06:26AM Prime Medicine, Inc. (PRME) Tops Q3 EPS by 5c

Oct 25, 2024 06:19AM BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)

Oct 15, 2024 08:02AM Prime Medicine (PRME) to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

Oct 4, 2024 07:19AM BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)

Oct 2, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)

Oct 1, 2024 07:35AM BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)

Sep 30, 2024 04:02PM Citi Reiterates Buy Rating on Prime Medicine (PRME)

Sep 30, 2024 03:06PM TD Cowen Reiterates Buy Rating on Prime Medicine (PRME)

Sep 30, 2024 11:49AM Jones Trading Reiterates Buy Rating on Prime Medicine (PRME)

Sep 30, 2024 07:05AM Prime Medicine (PRME) Unveils Strategically Focused Pipeline

Sep 30, 2024 07:04AM Prime Medicine (PRME) Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Aug 8, 2024 09:20AM Prime Medicine, Inc. (PRME) Tops Q2 EPS by 3c